Citadel Advisors
RYZB

Citadel Advisors’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Citadel Advisors’s Portfolio RYZB Stock Details RYZB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-54,009
Closed -$1.2M – 15541
2023
Q3 		$1.2M Buy
+54,009
New +$1.13M ﹤0.01% 6200

Other funds holding RYZB

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's RYZB Position: Q4 2023 in Review

Citadel Advisors sold out of RayzeBio, Inc. Common Stock (RYZB) in Q4 2023, closing a stake of 54,009 shares — an estimated $1.2M sold.

Citadel Advisors first reported a position in RYZB in Q3 2023 and held it in 1 quarter. The position peaked at $1.2M in Q3 2023. 107 funds tracked by Wall St. Rank hold RYZB as of Q4 2023.

  • Citadel Advisors reported no remaining RayzeBio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 54,009 RayzeBio, Inc. Common Stock shares in Q4 2023, an estimated $1.2M.
  • Citadel Advisors first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Citadel Advisors's RayzeBio, Inc. Common Stock position peaked at $1.2M in Q3 2023.
  • 107 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.